...
首页> 外文期刊>Journal of Biomolecular Structure and Dynamics >Molecular perception of interactions between bis(7)tacrine and cystamine-tacrine dimer with cholinesterases as the promising proposed agents for the treatment of Alzheimer's disease
【24h】

Molecular perception of interactions between bis(7)tacrine and cystamine-tacrine dimer with cholinesterases as the promising proposed agents for the treatment of Alzheimer's disease

机译:bis(7)他克林与胱胺酯-他克林二聚体与胆碱酯酶之间相互作用的分子感知,可作为拟议的治疗阿尔茨海默氏病的药物

获取原文
获取原文并翻译 | 示例
           

摘要

The infamous chronic neurodegenerative disease, Alzheimer's, that starts with short-term memory loss and eventually leads to gradual bodily function decline which has been attributed to the deficiency in brain neurotransmitters, acetylcholine, and butylcholine. As a matter of fact, design of compounds that can inhibit cholinesterases activities (acetylcholinesterase and butylcholinesterase) has been introduced as an efficient method to treat Alzheimer's. Among proposed compounds, bis(7)tacrine (B7T) is recognized as a noteworthy suppressor for Alzheimer's disease. Recently a new analog of B7T, cystamine-tacrine dimer is offered as an agent to detain Alzheimer's complications, even better than the parent compound. In this study, classical molecular dynamic simulations have been employed to take a closer look into the modes of interactions between the mentioned ligands and both cholinesterase enzymes. According to our obtained results, the structural differences in the target enzymes active sites result in different modes of interactions and inhibition potencies of the ligands against both enzymes. The obtained information can help to investigate those favorable fragments in the studied ligands skeletons that have raised the potency of the analog in comparison with the parent compound to design more potent multi target ligands to heal Alzheimer's disease.
机译:臭名昭著的慢性神经退行性疾病,阿尔茨海默氏病,始于短期记忆丧失,最终导致身体机能逐渐下降,这归因于脑神经递质,乙酰胆碱和丁胆碱的缺乏。实际上,已经设计出可以抑制胆碱酯酶活性的化合物(乙酰胆碱酯酶和丁基胆碱酯酶)作为治疗阿尔茨海默氏病的有效方法。在提出的化合物中,双(7)他克林(B7T)被认为是阿尔茨海默氏病的重要抑制剂。最近,提供了一种新的B7T类似物胱胺-他克林二聚体作为阻止老年痴呆症并发症的药物,甚至优于母体化合物。在这项研究中,经典的分子动力学模拟已被用来仔细研究所提到的配体与两种胆碱酯酶之间的相互作用模式。根据我们获得的结果,靶酶活性位点的结构差异导致配体针对两种酶的相互作用方式和抑制能力不同。获得的信息可以帮助研究与母体化合物相比提高了类似物效价的被研究配体骨架中那些有利的片段,以设计更有效的多靶标配体来治愈阿尔茨海默氏病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号